| Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery Y Zhao, Y Shang, W Song, Q Li, H Xie, Q Xu, J Jia, L Li, H Mao, X Zhou, ... EClinicalMedicine 25, 2020 | 969 | 2020 |
| Blocking of the PD‐1/PD‐L1 Interaction by a D‐Peptide Antagonist for Cancer Immunotherapy HN Chang, BY Liu, YK Qi, Y Zhou, YP Chen, KM Pan, WW Li, XM Zhou, ... Angewandte Chemie International Edition 54 (40), 11760-11764, 2015 | 336 | 2015 |
| A Novel d‐Peptide Identified by Mirror‐Image Phage Display Blocks TIGIT/PVR for Cancer Immunotherapy X Zhou, C Zuo, W Li, W Shi, X Zhou, H Wang, S Chen, J Du, G Chen, ... Angewandte Chemie International Edition 59 (35), 15114-15118, 2020 | 96 | 2020 |
| Intrinsic expression of immune checkpoint molecule TIGIT could help tumor growth in vivo by suppressing the function of NK and CD8+ T cells XM Zhou, WQ Li, YH Wu, L Han, XG Cao, XM Yang, HF Wang, WS Zhao, ... Frontiers in immunology 9, 405294, 2018 | 91 | 2018 |
| CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy H Wang, Y Sun, X Zhou, C Chen, L Jiao, W Li, S Gou, Y Li, J Du, G Chen, ... Journal for immunotherapy of cancer 8 (2), 2020 | 82 | 2020 |
| A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses W Zhai, X Zhou, H Wang, W Li, G Chen, X Sui, G Li, Y Qi, Y Gao Acta Pharmaceutica Sinica B 10 (6), 1047-1060, 2020 | 57 | 2020 |
| A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy Z Yan, Y Wu, J Du, G Li, S Wang, W Cao, X Zhou, C Wu, D Zhang, X Jing, ... Oncotarget 7 (26), 40437, 2016 | 56 | 2016 |
| Engineered Nanovaccine Targeting Clec9a+ Dendritic Cells Remarkably Enhances the Cancer Immunotherapy Effects of STING Agonist S Gou, W Liu, S Wang, G Chen, Z Chen, L Qiu, X Zhou, Y Wu, Y Qi, Y Gao Nano Letters 21 (23), 9939-9950, 2021 | 53 | 2021 |
| An orally available PD-1/PD-L1 blocking peptide OPBP-1-loaded trimethyl chitosan hydrogel for cancer immunotherapy W Li, X Zhu, X Zhou, X Wang, W Zhai, B Li, J Du, G Li, X Sui, Y Wu, M Zhai, ... Journal of Controlled Release 334, 376-388, 2021 | 47 | 2021 |
| Characterization of CD103+ CD8+ tissue-resident T cells in esophageal squamous cell carcinoma: may be tumor reactive and resurrected by anti-PD-1 blockade L Han, QL Gao, XM Zhou, C Shi, GY Chen, YP Song, YJ Yao, YM Zhao, ... Cancer Immunology, Immunotherapy 69, 1493-1504, 2020 | 42 | 2020 |
| Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy W Zhai, X Zhou, M Zhai, W Li, Y Ran, Y Sun, J Du, W Zhao, L Xing, Y Qi, ... Science China Life Sciences 64, 548-562, 2021 | 32 | 2021 |
| Dual blockade of lactate/GPR81 and PD-1/PD-L1 pathways enhances the anti-tumor effects of metformin S Chen, X Zhou, X Yang, W Li, S Li, Z Hu, C Ling, R Shi, J Liu, G Chen, ... Biomolecules 11 (9), 1373, 2021 | 25 | 2021 |
| Extracellular vesicle IL-32 promotes the M2 macrophage polarization and metastasis of esophageal squamous cell carcinoma via FAK/STAT3 pathway Y Sun, Y Qian, C Chen, H Wang, X Zhou, W Zhai, L Qiu, X Zhou, H Ning, ... Journal of Experimental & Clinical Cancer Research 41 (1), 145, 2022 | 24 | 2022 |
| Rational design of potent peptide inhibitors of the PD-1: PD-L1 interaction for cancer immunotherapy H Yin, X Zhou, YH Huang, GJ King, BM Collins, Y Gao, DJ Craik, ... Journal of the American Chemical Society 143 (44), 18536-18547, 2021 | 23 | 2021 |
| Repositioning azelnidipine as a dual inhibitor targeting CD47/SIRPα and TIGIT/PVR pathways for cancer immuno-therapy X Zhou, L Jiao, Y Qian, Q Dong, Y Sun, WV Zheng, W Zhao, W Zhai, L Qiu, ... Biomolecules 11 (5), 706, 2021 | 23 | 2021 |
| In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1 W Zhai, X Zhou, J Du, Y Gao Methods in Enzymology 629, 361-381, 2019 | 23 | 2019 |
| Tryptophan 2, 3-dioxygenase 2 controls M2 macrophages polarization to promote esophageal squamous cell carcinoma progression via AKT/GSK3β/IL-8 signaling pathway Y Zhao, J Sun, Y Li, X Zhou, W Zhai, Y Wu, G Chen, S Gou, X Sui, W Zhao, ... Acta Pharmaceutica Sinica B 11 (9), 2835-2849, 2021 | 21 | 2021 |
| Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR X Zhou, J Du, H Wang, C Chen, L Jiao, X Cheng, X Zhou, S Chen, S Gou, ... Cell Communication and Signaling 18, 1-14, 2020 | 21 | 2020 |
| A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapy L Jiao, Q Dong, W Zhai, W Zhao, P Shi, Y Wu, X Zhou, Y Gao Pharmacological Research 182, 106343, 2022 | 18 | 2022 |
| Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy W Shen, P Shi, Q Dong, X Zhou, C Chen, X Sui, W Tian, X Zhu, X Wang, ... Journal for Immunotherapy of Cancer 11 (6), 2023 | 14 | 2023 |
